2013 Fiscal Year Final Research Report
The role of HSP27 in the anti-tumor action of gemcitabine for pancreatic cancer
| Project/Area Number |
23591013
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Gifu University |
|---|
Principal Investigator |
YASUDA Ichiro 岐阜大学, 医学(系)研究科(研究院), 准教授 (00377673)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOZAWA Osamu 岐阜大学, 大学院医学系研究科, 教授 (90225417)
ADACHI Seiji 岐阜大学, 大学院医学系研究科, 非常勤 講師 (50467205)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 膵癌 / Gemcitabine / HSP27 / EUS-FNA |
|---|
| Research Abstract |
We here revealed that phosphorylated HSP27 (P-HSP27) played a key role in gemcitabine (GEM)-induced apoptosis in pancreatic cancer derived cell line. Furthermore, the level of P-HSP27 was a factor to determine the sensitivity to GEM from the results of siRNA and inhibitor experiments. In addition, we examine the clinical significance of investigating the expression levels of HSP27 or P-HSP27 in the biopsied specimen of the pancreatic cancer using endoscopic ultrasound -guided fine needle aspiration (EUS-FNA) technique. As a result, the expression level of P-HSP27 was associated with the absence of metastasis and longer survival. These results suggest that the evaluation of the P-HSP27 expression in the biopsy specimen can be a prognostic factor to predict the prognosis. On the other hand, it was failed to proven that the expression level of HSP27 or P-HSP27 was a factor to predict the response to GEM chemotherapy.
|
